Podium to Practice: GI Cancers Symposium 2026 – HERIZON-GEA-01

Podium to Practice: GI Cancers Symposium 2026 – HERIZON-GEA-01

Podium to Practice: GI Cancers Symposium 2026
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Scott Berry

Icon Chair Speaker

Panelists

Dr. Sharlene Gill

Dr. Marc Peeters

Studies / Trials Discussed

LBA285 – Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.

Studies/trials discussed:

LBA285 – Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.
Tagged